We focus on research because the link between research spending and improved survival is clear. Survival rates have dramatically improved for colorectal, breast, and prostate cancers over the last several decades in step with the exponential growth in their research spending. Our goal is to accelerate progress for lung cancer in the same way, in order to dramatically improve on the current 17% five-year survival rate.

To date, LUNGevity has funded 110 research projects at 57 institutions in 23 states. LUNGevity research investments focus on early detection, because survival rates rise when lung cancer is detected while still localized. We also focus on more effective treatment approaches—getting the right treatment to the right patient at the right time to help people with lung cancer live longer and better.

Our projects are translational, moving basic research from the lab to patient treatment. We fund the projects most likely to have the greatest benefit for patients in the near term. Thanks to our Scientific Advisory Board—a group that includes leaders in early detection, genomics, proteomics, immunotherapy, biostatistics, and thoracic surgery—research project applications are rigorously reviewed in a robust, transparent process and then funded projects are carefully monitored. Through ongoing work with researchers across the various institutions, LUNGevity maximizes the progress and impact of ongoing studies.

LUNGevity also provides a community of empowerment, support, and hope for everyone affected by lung cancer through our extensive educational resources, online peer-to-peer support, and in-person survivorship programs, as well as more than 80 grassroots awareness and fundraising events held from coast to coast each year.